These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27543467)

  • 1. Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy.
    Wayangankar SA; Roe MT; Chen AY; Gupta RS; Giugliano RP; Newby LK; de Lemos JA; Alexander KP; Sanborn TA; Saucedo JF
    Indian Heart J; 2016; 68(4):464-72. PubMed ID: 27543467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States.
    Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Patel D; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2017 Sep; 10(9):. PubMed ID: 28855222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
    Stone GW; Clayton T; Deliargyris EN; Prats J; Mehran R; Pocock SJ
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):15-20. PubMed ID: 24140664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
    Auffret V; Leurent G; Boulmier D; Bedossa M; Zabalawi A; Hacot JP; Coudert I; Filippi E; Castellant P; Rialan A; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Le Guellec M; Gilard M; Le Breton H
    Arch Cardiovasc Dis; 2016 Dec; 109(12):696-707. PubMed ID: 27818120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention.
    Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C
    Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry.
    Lopes RD; Peterson ED; Chen AY; Roe MT; Wang TY; Ohman EM; Magid DJ; Ho PM; Wiviott SD; Scirica BM; Alexander KP
    JACC Cardiovasc Interv; 2010 Jun; 3(6):669-77. PubMed ID: 20630461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding complications with regional adaptation of a prolonged bivalirudin regimen for ST-elevation acute myocardial infarction.
    Mueller E; Prabhu W; Desarno M; Sundaran P; Dauerman H
    Am J Cardiol; 2012 Dec; 110(11):1607-12. PubMed ID: 22901969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Witzenbichler B; Mehran R; Guagliumi G; Dudek D; Huber K; Kornowski R; Stuckey TD; Fahy M; Parise H; Stone GW
    JACC Cardiovasc Interv; 2011 Jul; 4(7):760-8. PubMed ID: 21777884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
    Bangalore S; Cohen DJ; Kleiman NS; Regev-Beinart T; Rao SV; Pencina MJ; Mauri L;
    Circ Cardiovasc Interv; 2011 Oct; 4(5):463-73. PubMed ID: 21972401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial).
    Tsujita K; Nikolsky E; Lansky AJ; Dangas G; Fahy M; Brodie BR; Dudek D; Möckel M; Ochala A; Mehran R; Stone GW
    Am J Cardiol; 2010 May; 105(10):1385-94. PubMed ID: 20451683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).
    Parodi G; Migliorini A; Valenti R; Bellandi B; Signorini U; Moschi G; Buonamici P; Cerisano G; Antoniucci D
    Am J Cardiol; 2010 Apr; 105(8):1053-9. PubMed ID: 20381652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).
    Erlinge D; Koul S; Eriksson P; Scherstén F; Omerovic E; Linder R; Östlund OP; Wallentin L; Fröbert O; James S
    Am Heart J; 2016 May; 175():36-46. PubMed ID: 27179722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.
    Pinto DS; Ogbonnaya A; Sherman SA; Tung P; Normand SL
    Circ Cardiovasc Qual Outcomes; 2012 Jan; 5(1):52-61. PubMed ID: 22235065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials).
    Ng VG; Baumbach A; Grinfeld L; Lincoff AM; Mehran R; Stone GW; Lansky AJ
    Am J Cardiol; 2016 Jan; 117(2):186-91. PubMed ID: 26704028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of anticoagulants and outcomes in STEMI patients undergoing PPCI in the US hospitals: Bivalirudin, heparin plus GPI or heparin alone?
    Plent S; Mitchell M; Fan W; Werner R
    Hosp Pract (1995); 2015; 43(3):164-71. PubMed ID: 26190670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding outcomes after routine transradial primary angioplasty for acute myocardial infarction using eptifibatide and unfractionated heparin: a single-center experience following the HORIZONS-AMI trial.
    Moody WE; Chue CD; Ludman PF; Chan YK; Narayan G; Millington JM; Townend JN; Doshi SN
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E138-47. PubMed ID: 23074143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.